Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
iTind™ Procedure Available to More Patients through Extended Commercial Payer Coverage | ||
By: PR Newswire Association LLC. - 16 Apr 2024 | Back to overview list |
|
Policy updates extend coverage to as many as 27 million enrollees nationwide CENTER VALLEY, Pa., April 16, 2024 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today positive changes to commercial payer policies covering patients who could benefit from the iTind™ procedure, a minimally invasive treatment for the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), also known as enlarged prostate. Most notably, Aetna,i a CVS Health company, updated its Clinical Policy Bulletin 0079 for Benign Prostatic Hyperplasia to include the iTind procedure as medically necessary in cases where the prostate volume is between 25 and 75 g, and there is a lack of obstruction in the median lobe. This policy update affects 25 million lives covered nationwide.1 In addition, three regional health plans updated their policies. These positive policy updates affect approximately 2 million more lives across Delaware, Florida, North Carolina, Pennsylvania, South Carolina and Washington, DC. The positive commercial payer policy changes remove barriers to access for physicians who recommend the iTind procedure to their BPH patients, as well as for patients seeking a proven alternative to more invasive treatment options or pharmaceuticals that may come with unwanted side effects. The policy updates increase the likelihood of the iTind procedure being covered by payers and fosters greater adoption by both patients and physicians seeking safe and effective treatment for BPH. "We are very pleased to see these positive coverage updates for the iTind procedure," said Paul Skodny, PharmD, Executive Director for Health Economics and Market Access at Olympus Corporation. "Olympus is committed to supporting physicians and patients in accessing recommended and proven BPH therapies like the iTind procedure." Clinical Evidence Olympus UNITE Patient Access Program AUA Guidelines The iTind™ procedure involves the placement of a temporarily implanted nitinol device that reshapes the prostatic urethra without burning or cutting out the prostate. The device can be placed in an outpatient setting or physician office. It remains in place for five to seven days while the patient is at home. Upon removal, patients experience rapid and effective relief of their symptoms.2,3,6 The iTind procedure may not be for everyone. Please consult with a doctor to see if the iTind procedure is right for you. As with any medical procedure, implantation of the iTind device comes with the possibility of side effects, including pelvic discomfort, blood in urine, and/or painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate. More information about the iTind procedure is available at BPHTherapy.com/iTind. About Olympus For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit olympusamerica.com. ________________________ i Trademarks and Service Marks are property of their respective owners and do not imply endorsement. View original content to download multimedia:https://www.prnewswire.com/news-releases/itind-procedure-available-to-more-patients-through-extended-commercial-payer-coverage-302118255.html SOURCE Olympus Corporation of the Americas |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |